Glandular lesions of the cervix in clinical practice: A cytology, histology, and human papillomavirus correlation study from 2 institutions

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 11, 2015, Pages 1431-1436

  Miller, Ross A ^a,b   Mody, Dina R ^b   Tams, Kimberlee C ^c   Thrall, Michael J ^b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84945910541     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0633-OA     Document Type: Conference Paper

References (30)

1. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010; 16 (3): 217-230.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2007 Incidence and Mortality Web-Based Report. Atlanta, GA: Dept of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2010.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute Web site. http://seer.cancer.gov/csr/1975-2011/. Accessed September 14, 2014.
4. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening: Second edition-summary document. Ann Oncol. 2010; 21 (3): 448-458.
5. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000; 88 (10): 2283-2289.
6. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States: Relation to incidence and survival. Cancer. 2005; 103 (6): 1258-1264.
7. Hemminki K, Li X, Mutanen P. Age-incidence relationships and time trends in cervical cancer in Sweden. Eur J Epidemiol. 2001; 17 (4): 323-328.
8. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinomass relative to squamous cell carcinoma of the uterine cervix in the United States, a 24-year population based-study. Gynecol Oncol. 2000; 78 (2): 97-105.
9. DeMay M. The Art and Science of Cytopathology. 2nd ed. Chicago, IL: American Society for Clinical Pathology Press; 2012.
10. Mody DR. Diagnostic Pathology: Cytopathology. Altona, MB: Amirsys Publishing; 2014.
11. Vale DB, Braganca JF, Morais SS, Zeferino LC. Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: A cross-sectional study. Int J Gynecol Cancer. 2014; 24 (2): 321-328.
12. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189 (1): 12-19.
13. Bosch FX, Muñoz N. The viral etiology of cervical cancer. Virus Res. 2002; 89 (2): 183-190.
14. Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012; 62 (3): 147-172.
15. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: A randomized controlled trial. JAMA. 2009; 302 (16): 1757-1764.
16. Wright TC, Schiffman M, Solomen D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004; 103 (2): 304-309.
17. Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014; 120 (13): 2032-2038.
18. FDA approves first human papillomavirus test for primary cervical cancer screening [news release]. US Food and Drug Administration Web site. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm394773.htm. Published April 24, 2014. Accessed September 16, 2014.
19. Microbiology Devices Panel of the Medical Devices Advisory Committee: March 12, 2014 meeting. US Food and Drug Administration Web site. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/MicrobiologyDevicesPanel/ucm388531.htm. Accessed September 16, 2014.
20. Giorgi Rossi P, Sideri M, Carozzi FM, et al. HPV type distribution in invasive cervical cancers in Italy: Pooled analysis of three large studies. Infect Agents Cancer. 2012; 7 (1): 26.
21. Tjalma WA, Fiander A, Reich O, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013; 132 (4): 854-867.
22. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11 (11): 1048-1056.
23. Zhao C, Yang H, Li Z. Cytopathology and more: Evidence emerging for HPV-negative cervical cancer. CAP Today. 2014: 28 (1). http://www.captodayonline.com/cytopathology-And-more-evidence-emerging-for-hpvnegative-cervical-cancer/. Accessed September 16, 2014.
24. Miller RA, Waters LL, Mody DR, Tams KC. Squamous cell carcinoma of the cervix: A cytology-histology-HPV correlation in clinical practice. Arch Pathol Lab Med. 2015; 139 (6): 776-781.
25. Li Z, Austin RM, Guo M, Zhao C. Screening test results associated with cancer diagnosis in 287 women with cervical squamous cell carcinoma. Arch Pathol Lab Med. 2012; 136 (12): 1533-1540.
26. Herbert A, Anshu, Gregory M, Gupta SS, Singh N. Invasive cervical cancer audit: A relative increase in interval cancers while coverage increased and incidence declined. BJOG. 2009; 116 (6): 845-853.
27. College of American Pathologists cervicovaginal cytology benchmarks 2011. http://www.cap.org/apps/docs/proficiency-testing/CYP07600.pdf. Accessed February 4, 2015.
28. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol. 2001; 65: 155-162.
29. Renshaw AA. Measuring sensitivity in gynecologic cytology: A review. Cancer Cytopathol. 2002; 96 (4): 210-217.
30. Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics. 1983; 39 (1): 207-215.